CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 125 enrolled
Drug / intervention
Imatinib Mesylate (Gleevec)drug
Likely dose
Imatinib mesylate 400 mg orally daily; HES patients start with 100 mg orally dailyAI-extracted
Key inclusion· 6
  • ✓One of the following diagnoses: hypereosinophilic syndrome (HES), polycythemia vera (PV), atypical CML or CMML with PDGF-R fusion genes, or mastocytosis
  • ✓ECOG performance status less than 3
  • ✓Life expectancy greater than 12 weeks
  • ✓NYHA Class less than 3
Key exclusion· 0

None specified.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00038675
NCT00038675N/ACompleted
CompareCT.gov

Therapy of Hypereosinophilic Syndrome, Polycythemia Vera, Atypical CML or CMML With Platelet Derived Growth Factor (PDGF-R) Fusion Genes, or Mastocytosis With Imatinib Mesylate (STI571)

M.D. Anderson Cancer Center·interventional·Posted Jun 5, 2002·Updated Jan 4, 2022

In Brief

A clinical study evaluating Imatinib Mesylate (Gleevec) for Chronic Myelomonocytic Leukemia and 4 related conditions. Completed, enrolled 125 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to see if Gleevec, known as imatinib mesylate (STI571), can improve the disease condition in patients with hypereosinophilic syndrome, polycythemia vera, atypical CML or CMML with PDGF-R fusion genes, or mastocytosis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Myelomonocytic Leukemia, Chronic Myeloid Leukemia, Polycythemia Vera, Hypereosinophilic Syndrome, Mastocytosis
CountriesUnited States
CollaboratorsNovartis Pharmaceuticals

Timeline

N/ACompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 5, 2002
Enrollment StartJun 1, 2001
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 12.4 yearsPosted 24.1 years ago

Interventions

Imatinib Mesylate (Gleevec)drug

Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily